FDA APPROVES GENENTECH’S TECENTRIQ IN COMBINATION WITH A FLUOROPYRIMIDINE AND OXALIPLATIN FOR THE ADJUVANT TREATMENT OF A CERTAIN TYPE OF STAGE III COLON CANCER

Reuters · 3d ago

Please log in to view news